The European Medicines Agency's Committee for Medicinal Products for Human Use said Friday it recommended an extension of therapeutic indication for Beigene's (ONC) cancer drug Tevimbra.
Tevimbra is already authorized in the EU, the committee said, with indications for non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, and oesophageal squamous cell carcinoma.
Price: 240.05, Change: +1.29, Percent Change: +0.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.